jane-kelly-shutterstock-com
JANE KELLY / SHUTTERSTOCK.COM
2 June 2016PharmaJane Wainwright and Tom Harding

In or out? How UK and European politics are shaking IP all about

Political issues around the world have long played a major role in shaping all areas of law and science, and neither intellectual property nor the life sciences have been immune to this. There is currently, however, a heightened level of political influence on IP in Europe and in particular the UK. Significant political battles are being fought in relation to UK membership of the EU and the unitary patent system, as well as more minor lobbying in other areas such as supplementary protection certificates (SPCs).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
1 October 2026   The decision leaves a $177 million verdict against Lilly intact, but a dissenting judge has warned the ruling could “undermine medical innovation” by allowing overly broad patent claims to survive and provide a way around the Supreme Court’s Amgen decision.
Pharma
28 September 2026   Can a drug’s ‘inactive’ precursor qualify for a multi-million pound patent extension? The UK High Court has just delivered a ruling on Takeda's ADHD drug Elvanse, weighing regulatory precedent against a conflicting German decision.
Pharma
25 September 2026   Another Wegovy patent has been drawn into the long-running dispute between Mylan and Novo Nordisk over proposed generic versions of the weight-loss drug.